Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study-Reference-Cited by-同舟云学术

Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study

Published:2009-12-27 Issue:4 Volume:25 Page:1200-1206
ISSN:0931-0509
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:Nephrology Dialysis Transplantation

Author:

Tsakiris D. J.,Stel V. S.,Finne P.,Fraser E.,Heaf J.,de Meester J.,Schmaldienst S.,Dekker F.,Verrina E.,Jager K. J.

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ndt/article-pdf/25/4/1200/5265165/gfp679.pdf

Reference31 articles.

1. Multiple Myeloma

2. Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945.

3. Comparison of Trends in the Incidence of Multiple Myeloma in Malmö, Sweden, and Other Countries, 1950–1979

4. Multiple Myeloma

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autologous stem cell transplantation in newly diagnosed multiple myeloma patients with severe renal failure requiring hemodialysis. A single-center experience;Oncohematology;2024-09-02

2. Kidney Transplantation in Multiple Myeloma and Monoclonal Gammopathy of Renal Significance;Seminars in Nephrology;2024-01

3. Real-life experience with plasmapheresis in newly diagnosed multiple myeloma accompanied by acute kidney injury;Irish Journal of Medical Science (1971 -);2023-09-28

4. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial;Cancers;2023-09-21

5. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group;The Lancet Oncology;2023-07